http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 18:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++TuHURA+Biosciences%2C+Inc.+++++++++++++++Filed+by%3A+Bianco+James+A./26999265.html si-local-file:///var/storage/secattach/20260828/26999265.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++TuHURA+Biosciences%2C+Inc.+++++++++++++++Filed+by%3A+Bianco+James+A./26999265.html Fri, 28 Aug 2026 18:02:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++TuHURA+Biosciences%2C+Inc.+++++++++++++++Filed+by%3A+Bianco+James+A./26999265.html si-local-file:///var/storage/secattach/20260828/26999265.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++TuHURA+Biosciences%2C+Inc.+++++++++++++++Filed+by%3A+Bianco+James+A./26999265.html Fri, 28 Aug 2026 18:02:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+20/26962307.html si-local-file:///var/storage/secattach/20260821/26962307.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+20/26962307.html Fri, 21 Aug 2026 17:00:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+20/26962307.html si-local-file:///var/storage/secattach/20260821/26962307.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+20/26962307.html Fri, 21 Aug 2026 17:00:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+18/26950949.html si-local-file:///var/storage/secattach/20260819/26950949.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+18/26950949.html Wed, 19 Aug 2026 17:00:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+18/26950949.html si-local-file:///var/storage/secattach/20260819/26950949.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+18/26950949.html Wed, 19 Aug 2026 17:00:00 -0400 HURA O.10076388 http://www.streetinsider.com/Analyst+Comments/TuHURA+Biosciences+%28HURA%29+Reiterated+at+Market+Outperform+by+Citizens+/26939652.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $9.00 price target on TuHURA Biosciences (NASDAQ: HURA).</p><p>The analyst commented, "TuHURA is focused on several novel approaches based on myeloid biology as well as a legacy product in Phase 3 development. Development of IFx-2.0 is ongoing and HURA has an aligned with the FDA on a path to the market that includes the potential to reach the market without a confirmatory study, based on PFS data of the Phase 3. TuHura's next-generation assets focus on a novel approach to AML, via targeting of immunosuppresive phenotype and reprogramming of the TME. http://www.streetinsider.com/Analyst+Comments/TuHURA+Biosciences+%28HURA%29+Reiterated+at+Market+Outperform+by+Citizens+/26939652.html Tue, 18 Aug 2026 04:15:50 -0400 HURA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TuHURA+Biosciences%2C+Inc.++For%3A+Jun+30/26924845.html si-local-file:///var/storage/secattach/20260814/26924845.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TuHURA+Biosciences%2C+Inc.++For%3A+Jun+30/26924845.html Fri, 14 Aug 2026 08:02:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TuHURA+Biosciences%2C+Inc.++For%3A+Jun+30/26924845.html si-local-file:///var/storage/secattach/20260814/26924845.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TuHURA+Biosciences%2C+Inc.++For%3A+Jun+30/26924845.html Fri, 14 Aug 2026 08:02:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+14/26924672.html si-local-file:///var/storage/secattach/20260814/26924672.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+14/26924672.html Fri, 14 Aug 2026 07:50:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+14/26924672.html si-local-file:///var/storage/secattach/20260814/26924672.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+14/26924672.html Fri, 14 Aug 2026 07:50:00 -0400 HURA O.10076388 http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended <chron>June 30, 2026</chron>, and provided a corporate update. </p><p>"We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year," said Dr. <person>James Bianco</person>, President and CEO of <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences</span>. "In the second http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html Fri, 14 Aug 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended <chron>June 30, 2026</chron>, and provided a corporate update. </p><p>"We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year," said Dr. <person>James Bianco</person>, President and CEO of <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences</span>. "In the second http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html Fri, 14 Aug 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended <chron>June 30, 2026</chron>, and provided a corporate update. </p><p>"We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year," said Dr. <person>James Bianco</person>, President and CEO of <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences</span>. "In the second http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html Fri, 14 Aug 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended <chron>June 30, 2026</chron>, and provided a corporate update. </p><p>"We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year," said Dr. <person>James Bianco</person>, President and CEO of <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences</span>. "In the second http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html Fri, 14 Aug 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended <chron>June 30, 2026</chron>, and provided a corporate update. </p><p>"We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year," said Dr. <person>James Bianco</person>, President and CEO of <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences</span>. "In the second http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html Fri, 14 Aug 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended <chron>June 30, 2026</chron>, and provided a corporate update. </p><p>"We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year," said Dr. <person>James Bianco</person>, President and CEO of <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences</span>. "In the second http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html Fri, 14 Aug 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended <chron>June 30, 2026</chron>, and provided a corporate update. </p><p>"We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year," said Dr. <person>James Bianco</person>, President and CEO of <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences</span>. "In the second http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html Fri, 14 Aug 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended <chron>June 30, 2026</chron>, and provided a corporate update. </p><p>"We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year," said Dr. <person>James Bianco</person>, President and CEO of <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences</span>. "In the second http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26924637.html Fri, 14 Aug 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+07/26922500.html si-local-file:///var/storage/secattach/20260813/26922500.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+07/26922500.html Thu, 13 Aug 2026 17:01:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+07/26922500.html si-local-file:///var/storage/secattach/20260813/26922500.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Aug+07/26922500.html Thu, 13 Aug 2026 17:01:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Jul+28/26836290.html si-local-file:///var/storage/secattach/20260729/26836290.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Jul+28/26836290.html Wed, 29 Jul 2026 17:00:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Jul+28/26836290.html si-local-file:///var/storage/secattach/20260729/26836290.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Jul+28/26836290.html Wed, 29 Jul 2026 17:00:00 -0400 HURA O.10076388 http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+to+Present+at+Canaccord+Genuity%27s+46th+Annual+Growth+Conference/26798349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that <person>James A. Bianco</person>, M.D., President and Chief Executive Officer of TuHURA will present at the Canaccord Genuity's 46^th Annual Growth Conference taking place in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA.</location></p><p><b>Canaccord Genuity 46</b><b>^th</b><b> Annual Growth Conference</b></p><div><table border="0" cellspacing="0" cellpadding="1" class="prnbcc"><tr><td class="prngen2" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Date:           </span></p></td><td class="prngen2" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><chron>Wednesday, August 12, 2026</chron></span></p></td></tr><tr><td class="prngen2" colspan="1" rowspan="1"><p class="prnml4"><span http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+to+Present+at+Canaccord+Genuity%27s+46th+Annual+Growth+Conference/26798349.html Wed, 22 Jul 2026 07:40:00 -0400 A.50200196 HURA O.10076388 O.22572961 http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+to+Present+at+Canaccord+Genuity%27s+46th+Annual+Growth+Conference/26798349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that <person>James A. Bianco</person>, M.D., President and Chief Executive Officer of TuHURA will present at the Canaccord Genuity's 46^th Annual Growth Conference taking place in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA.</location></p><p><b>Canaccord Genuity 46</b><b>^th</b><b> Annual Growth Conference</b></p><div><table border="0" cellspacing="0" cellpadding="1" class="prnbcc"><tr><td class="prngen2" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Date:           </span></p></td><td class="prngen2" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><chron>Wednesday, August 12, 2026</chron></span></p></td></tr><tr><td class="prngen2" colspan="1" rowspan="1"><p class="prnml4"><span http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+to+Present+at+Canaccord+Genuity%27s+46th+Annual+Growth+Conference/26798349.html Wed, 22 Jul 2026 07:40:00 -0400 A.50200196 HURA O.10076388 O.22572961